Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcus Biosciences, Inc. (NYSE: RCUS) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on oncology and inflammatory and autoimmune diseases, Arcus uses SEC filings to report material clinical, financial and corporate events that can be important for investors analyzing RCUS stock.
Form 8‑K current reports frequently highlight significant developments in Arcus’s pipeline and capital structure. For example, 8‑K filings describe the discontinuation of the Phase 3 STAR‑221 trial and the Phase 2 EDGE‑Gastric study after an interim overall survival analysis showed no benefit for the domvanalimab plus zimberelimab and chemotherapy regimen compared with nivolumab plus chemotherapy. Other 8‑Ks detail updated data from the ARC‑20 Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma, including progression-free survival and response metrics, as well as safety findings.
Filings also cover financing and capital markets transactions. One Form 8‑K outlines an underwriting agreement for a public offering of common stock, including the number of shares sold, pricing and net proceeds. Another 8‑K describes a First Amendment to the company’s Loan and Security Agreement with Hercules Capital and other lenders, which restructures remaining term loan commitments into milestone-based tranches tied to Phase 3 data and potential FDA approval, extends the maturity date and adds performance covenants linked to market capitalization, qualified cash levels and potential net product revenue thresholds.
Investors can also use SEC filings to track collaboration and licensing arrangements, such as disclosures related to Arcus’s long-term collaboration with Gilead Sciences and its option and license agreement with Taiho Pharmaceutical. These documents may reference option exercises, milestone structures and rights to co-develop or commercialize investigational medicines like casdatifan, domvanalimab, zimberelimab and quemliclustat in specific territories.
Stock Titan’s interface surfaces these filings alongside AI-powered summaries that explain the practical implications of each document. Instead of parsing detailed legal language alone, readers can review concise explanations of how a loan amendment changes Arcus’s access to capital, what a trial discontinuation means for a particular program, or how a new data disclosure from a Phase 1/1b or Phase 3 study might influence the company’s development strategy. Real-time updates from EDGAR, combined with these AI insights, help users follow Arcus’s quarterly results, material clinical events, financing decisions and collaboration milestones directly from the underlying SEC record.
Arcus Biosciences, Inc. Chief Executive Officer and director reported automatic sales of company stock mainly to cover taxes tied to equity awards. On 12/16/2025, 28,947 shares of common stock were sold at a weighted average price of $21.8843, and on 12/17/2025, 25,744 shares were sold at a weighted average price of $22.1595, both coded as open-market sales. According to the footnotes, these transactions were carried out by the issuer on the executive’s behalf to satisfy tax withholding obligations upon the vesting of previously granted restricted stock units and were not discretionary trades by the executive.
After these transactions, the reporting person beneficially owned 2,194,809 shares of Arcus Biosciences common stock, which includes 236 shares acquired on November 30, 2025 through the company’s employee stock purchase plan and the unvested portion of outstanding RSU grants.
A shareholder of RCUS, Alexander Azoy, plans to sell 4,343 shares of common stock through Morgan Stanley Smith Barney on or about 12/18/2025 on the NYSE, with an aggregate market value of $96,762.04, compared with 107,973,536 shares outstanding.
The shares to be sold were acquired from the issuer on 12/15/2025 as restricted stock units. The notice also lists recent Rule 10b5-1 sales in the past three months, including 1,900 shares sold on 11/26/2025 for $49,400 and 2,831 shares sold on 09/29/2025 for $36,803.
Arcus Biosciences, Inc. amended its loan agreement with Hercules Capital and other lenders to modify access to the remaining $150.0 million of term loan commitments and extend the debt maturity date to September 1, 2030. The amendment makes $25.0 million available at the company’s option through March 15, 2026 and another $25.0 million available through September 15, 2026. A further up to $50.0 million becomes available after a specified Phase 3 clinical data milestone that supports a U.S. FDA Biologics License Application or New Drug Application, and an additional up to $50.0 million becomes available after FDA approval of such an application, each within defined time windows.
If the aggregate outstanding principal of the term loans exceeds $200.0 million, starting with financials for the third quarter after FDA approval, Arcus must meet new performance covenants based on market capitalization, levels of “Qualified Cash,” or certain net product revenue thresholds.
Arcus Biosciences, Inc. is the issuer for a planned Rule 144 stock sale. A shareholder has filed to sell 10000 shares of Arcus common stock through E*TRADE Financial Corporation on the NYSE, with an aggregate market value listed as 219000 and an approximate sale date of 12/16/2025.
The shares to be sold come from 18799 restricted shares of common stock that vested on 12/15/2025, which were originally granted on 2/10/2025 by Arcus Biosciences, Inc. as compensation for services rendered. The form also includes a representation that the seller does not know of any undisclosed material adverse information about Arcus’s current or prospective operations.
Arcus Biosciences is the issuer in a Rule 144 notice covering a proposed sale of its common stock. The filing describes a planned sale of 15000 common shares through E*TRADE Financial Corporation on the NYSE, with an aggregate market value of
The shares to be sold were recently acquired through equity compensation. Four grants of restricted stock, originally awarded on 3/8/2022, 1/23/2023, 1/23/2024 and 1/23/2025, vested on 12/15/2025 in return for services rendered. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the company’s current or prospective operations.
Arcus Biosciences, Inc. shareholder Alexander Azoy has filed a Rule 144 notice to sell 5000 shares of the company’s common stock through E*TRADE Financial Corporation on or about 12/16/2025. The planned sale has an aggregate market value of 109500, and the notice lists 122856086 Arcus common shares outstanding on the New York Stock Exchange.
The securities to be sold were acquired on 12/15/2025 through vesting of restricted stock grants originally awarded on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025 in exchange for services rendered, covering 1062, 1282, 2213, and 4275 shares respectively. The filing also reports that Azoy sold Arcus common stock in three prior transactions over the past three months, including 1900 shares on 11/26/2025 for gross proceeds of 49400 and 2831 shares on 09/29/2025 for gross proceeds of 36803.
A Rule 144 notice for Arcus Biosciences (RCUS) indicates that stockholder Robert C. Goeltz II plans to sell 14,000 shares of common stock through E*TRADE Financial on the NYSE, with an aggregate market value of 306,600 and an approximate sale date of 12/16/2025.
The shares to be sold come from restricted stock that vested on 12/15/2025 from grants originally awarded on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025 as consideration for services rendered. The notice also reports 122,856,086 shares outstanding and discloses additional recent sales by the same seller of 5,000 shares for gross proceeds of 125,000 on 11/26/2025 and 5,000 shares for 100,000 on 10/28/2025, providing context for his recent trading activity.
Arcus Biosciences, Inc. had a shareholder file a notice to sell 22000 shares of common stock through E*TRADE on the NYSE, with an aggregate market value of
The shares to be sold were acquired on
Arcus Biosciences, Inc. (RCUS) has a planned sale under Rule 144 for 22,000 shares of common stock through E*TRADE Financial Corporation, with an aggregate market value of 481,800. Shares outstanding were 122,856,086 as indicated in the notice; this is a baseline figure, not the planned sale amount, and the exchange named is NYSE. The approximate sale date is 12/16/2025.
The shares to be sold were acquired on 12/15/2025 through the vesting of restricted stock grants originally awarded on 3/8/2022 and 1/23 of 2023, 2024 and 2025 in exchange for services rendered. Over the prior three months, The Juan Carlos Jaen and Anita Galeana 2000 Trust reported several sales of Arcus common stock, including 82,997 shares on 12/04/2025 for gross proceeds of 2,096,504.22.
Arcus Biosciences, Inc. has a shareholder filing a notice under Rule 144 to sell up to 55,000 shares of common stock through broker E*TRADE Financial, with an aggregate market value of $1,204,500 and an approximate sale date of 12/16/2025 on the NYSE.
The notice states that the securities to be sold were acquired through vesting of restricted stock on 12/15/2025, granted on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025 as compensation for services rendered.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
